SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Knight Therapeutics Reports Third Quarter 2026 Results

Achieved nine-month record-high revenues of over $430 million and Adjusted EBITDA1 of over $76 milli

Related stories